The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...
Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...
Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, ...
The global CAR T-Cell Therapy for Multiple Myeloma market is experiencing transformative growth, driven by advances in BCMA-targeted therapies like FDA-approved Abecma and Carvykti. These treatments ...
Qihan's QT-019B program is supported by IND clearance for rSLE from both the US FDA and the China NMPA. The FDA has also granted Fast Track Designation for the SLE-ITP indication. Phase 1 enrollment ...
Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...
Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback